-+ 0.00%
-+ 0.00%
-+ 0.00%

Revelation Biosciences plans Phase 2a Gemini trial in acute kidney injury for early 2027

PUBT·11/16/2026 14:02:50
Listen to the news
Revelation Biosciences plans Phase 2a Gemini trial in acute kidney injury for early 2027
  • Revelation Biosciences plans a Phase 2a Gemini trial in stage 2 or 3 acute kidney injury patients in early 2027.
  • Topline results are expected in late 2027; earlier clinical studies showed reduced inflammatory activity and favorable tolerability.
  • The streamlined study is expected to cost approximately $7 million, compared with approximately $60 million under the previous development plan.
  • Planned licensing and development partnerships would support Gemini, which targets an estimated $94 billion addressable market in acute kidney injury.
  • Cash and cash equivalents totaled $9.1 million as of September 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611160900BIZWIRE_USPR_____20261116_BW471905) on November 16, 2026, and is solely responsible for the information contained therein.